Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers
Authors:
- 29 March 2015
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 240 (12) , 1572-1579
Abstract
Cisplatin, Cis-diamminedichloroplatinum (CDDP), is a platinum-based chemotherapy drug, and its chemotherapeutic use is restricted by nephrotoxicity. Inflammatory and apoptotic mechanisms play a central role in the pathogenesis of CDDP-induced acute kidney injury (AKI). The aim of this study was to compare the therapeutic potential of candesartan, angiotensin II receptor blocker, versus bone marrow-derived mesenchymal stem cells (BM-MSCs) in a rat model of CDDP-induced nephrotoxicity. Adult male Wistar rats (n = 40) were divided into four groups; Normal control: received saline injection, CDPP group: received CDDP injection (6 mg/kg single dose), Candesartan group: received candesartan (10 mg/kg/day) for 10 days + CDDP at day 3, and Stem cells group: received CDDP + BM-MSCs intravenously one day after CDDP injection. The rats were sacrificed seven days after CDDP injection. Significant elevation in serum creatinine and urea, renal levels of tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1, renal expressions of nuclear factor kappa B (NF-κB), p38-mitogen-activated protein kinase (MAPK), caspase-3 and Bcl-2-associated x protein (Bax) were found in CDDP-injected rats when compared to normal rats. Both candesartan and BM-MSCs ameliorated renal function and reduced significantly the inflammatory markers (TNF-α , NF-κB, p38-MAPK and MCP-1) and apoptotic markers (caspase-3 and Bax) in renal tissue after CDDP injection. Candesartan as well as BM-MSCs have anti-inflammatory and anti-apoptotic actions and they can be used as nephroprotective agents against CDDP-induced nephrotoxicity. BM-MSCs is more effective than candesartan in amelioration of AKI induced by CDDP.Keywords
This publication has 40 references indexed in Scilit:
- Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosisInternational Journal of Molecular Medicine, 2013
- Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1American Journal of Physiology-Renal Physiology, 2011
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- Immunosuppression by mesenchymal stem cells: mechanisms and clinical applicationsStem Cell Research & Therapy, 2010
- Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicityPharmacological Research, 2009
- Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockadeKidney International, 2008
- Regulation and Pathological Role of p53 in Cisplatin NephrotoxicityThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in MiceStem Cells, 2008
- Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing propertyMedical Hypotheses, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001